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Objectives: The aim of this study was to analyze the immunolabeling of two cell cycle protein regulators, p53 and p21WAF1, in non-dysplastic leukoplakias with 
different epithelial alterations: acanthosis, hyperkeratosis and acanthosis combined with 
hyperkeratosis, and compare them with dysplastic leukoplakias. Material and Methods: This 
was a prospective cohort study involving 36 patients with oral homogeneous leukoplakias. 
excisional biopsies were performed and the patients remain under clinical follow-up. The 
leukoplakias were divided into four groups: 6 acanthosis, 9 hyperkeratosis, 10 acanthosis 
combined with hyperkeratosis, and 11 epithelial dysplasias. Paraffin-embebeded sections 
were immunostained for p53 and p21WAF1. Five hundred cells from the basal layer and 
500 from the parabasal layer were counted to determine the percentage of positive 
cells. A qualitative analysis was also carried out to determine the presence or absence 
of immunohistochemical staining in the intermediate and superficial layers. Groups were 
compared with ANOVA (p<0.05). Pearson’s correlation coefficient was used to test for 
associations between the two markers, p53 and p21WAF1. Results: No leukoplakia recurred 
and no malignant transformation was observed whitin a follow-up period of 3-6 years. 
The mean percentage of p53 staining in the basal and parabasal layers was similar in all 
groups. p21WAF1 staining differed between layers was as follows: in the basal, only 3 to 4% 
of cells were stained, while in the parabasal, between 16 and 28% of the epithelial cells 
were stained in the four different studied groups with no statistically significant difference 
(p>0.05). Conclusions: Our findings failed to differentiate the non-dysplastic lesions by 
means of p53 and p21WAF1 immunostaining, notwithstanding similar profiles between non-
dysplastic and dysplastic leukoplakias were observed.
Key words: Leukoplakia. Oral cancer. Tumor suppressor protein p53. Cyclin-cependent 
Kinase inhibitor p21.
INTRODUCTION
Leukoplakia is the most common potentially 
malignant disorder of the oral mucosa. The World 
Health Organization (WHO) defines it as “a white 
patch or plaque that cannot be characterized, 
clinically or pathologically, as any other disease”. 
It is a diagnosis made by exclusion and to achieve 
the definitive histopathological diagnosis it must be 
complemented by incisional or excisional biopsy9.
epithelial dysplasia has always been considered 
one of the most important features concerning 
malignant transformation of oral leukoplakias, but, 
recent studies have shown a substantial amount (3.9 
to 11%) of non-dysplastic leukoplakias undergoing 
malignant progression7,8,20. Additionally, these 
studies have failed on confirming the relationship 
between grade of dysplasia and risk of malignant 
transformation.
Notwithstanding malignant transformation may 
also take place in non-dysplastic leukoplakia there is 
no information available in the literature considering 
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differences about behavior or risk of malignant 
transformation associated with each of the most 
common non-dysplastic abnormalities. Most studies 
evaluating the risk of malignant transformation have 
restricted their focus to the presence or absence of 
epithelial dysplasia and considered non-dysplastic 
leukoplakias as one single group, regardless of the 
different epithelial disorders observed13,24. 
Non-dysplastic leukoplakias may present several 
microscopic epithelial alterations. Waldron and 
Shafer28 (1975), after a microscopic analysis of 3,256 
leukoplakias, found that 80.1% showed different 
matches of hyperorthokeratosis, hyperparakeratosis 
and acanthosis and 16.7% of the leukoplakias 
presented epithelial dysplasia.
Leukoplakias may be characterized by a range 
of disorders in epithelial cell proliferation and 
differentiation19. One possible way to analyze 
alterations in non-dysplastic leukoplakias is by 
the assessment of proteins related to cell cycle 
control. Proliferation and differentiation processes 
are intimately related to cell cycle regulation, 
and changes in the machinery that regulates cell 
cycle may trigger the transformation to malignant 
neoplasms25.
The p53 protein, a product of the TP53 tumor 
suppressor gene, is expressed in the late G1 phase 
and arrests cell cycle progression to the S phase, 
to allow the repair of damaged DNA; if the damage 
persists or cannot be repaired, p53 will trigger cell 
death by apoptosis18. Because of its short half-life, 
p53 is found in low concentrations in epithelial cells. 
However, in potentially malignant disorders and 
oral cancer, an increase in its immunohistochemical 
labeling takes place, suggesting that changes in p53 
expression may be a characteristic of initial stages 
of oral carcinogenesis10,21.
In order to block the cell cycle, p53 induces 
transcription of the p21WAF1 protein, which is encoded 
by the WAF-1 gene. The p21WAF1 protein forms a 
quaternary complex with cyclin, cyclin-dependent 
kinase (CDK) and the proliferating cell nuclear 
antigen (PCNA), thereby bypassing phosphorylation 
of the pRb protein by the active cyclin-CDK complex 
and inhibiting progression of the cell cycle from 
G1 to phase S. Furthermore, when bound to the 
PCNA, p21WAF1 directly inhibits DNA replication 
during phase S5. The immunohistochemical labeling 
of p21WAF1 is also altered during the process of oral 
carcinogenesis, increasing in number and intensity 
as the severity of histological findings progresses. 
Therefore, it has been suggested that changes in 
p21WAF1 expression may contribute to, or reflect, 
carcinogenesis in oral epithelium3,22,30. 
The aim of this study was to evaluate the 
immunolabeling profile of p53 and p21WAF1 in non-
dysplastic leukoplakias: acanthosis, hyperkeratosis 
and acanthosis combined with hyperkeratosis, and 
compare them with dysplastic leukoplakias.
MATERIAL AND METhODS
The sample comprised lesions with a clinical 
diagnosis of leukoplakia obtained from patients 
treated at the Oral Pathology Department of the 
School of Dentistry of the Federal University of 
Rio Grande do Sul, Brazil, during a period of 3 
years. As inclusion criteria all patients in this study 
should present clinically a solitary and homogenous 
leukoplakia not exceeding 2 cm, in such a way that 
only excisional biopsies were performed to ensure 
that the histopathological diagnosis represented the 
true nature of the leukoplakia. exclusion criteria that 
removed patients from the sample were lesions with 
identified different sources of traumatic factors (for 
example frictional chronic irritation, trauma from an 
ill-fitting denture or other appliance, oclusal trauma 
from an opposing tooth, masticatory trauma from 
eating hard foods)2, presence of Candida albicans 
infection and presence of verrucous leukoplakia. 
The experiments were undertaken with the 
understanding and written consent of each subject 
and the patients remain under clinical follow-up.
All samples were fixed in 10% neutral buffered 
formalin. The biopsy fragments were sectioned 
longitudinally at their central portion, and, in the 
preparation of paraffin blocks, both fragments 
were positioned in such a way that the histological 
sections could show the whole extension of the 
epithelium in the center of the lesion. Sections were 
stained with HE and histopathological diagnoses 
were confirmed in accordance with the WHO 
classification for leukoplakias1, taking into account 
the anatomical site peculiarities.
Two 3-μm sections were obtained from each 
paraffin block for immunohistochemical staining. 
Sections were deparaffinized in xylene, rehydrated 
in alcohol and immersed in 0.3% hydrogen peroxide 
in methanol to block endogenous peroxidase. 
Antigen retrieval was performed for 20 min in 
a steamer (Arno, São Paulo, SP, Brazil) using 
a low-pH retrieval solution (DakoCytomation, 
Carpentaria, CA, USA). The slides were incubated 
at 25ºC for one hour with the monoclonal anti-p53 
(DO-7, 1:50, DakoCytomation) and monoclonal 
anti-p21WAF1 (SX118, 1:30, DakoCytomation) 
antibodies. The detection system used was 
enVision+ (DakoCytomation). Sections were 
counterstained with haematoxylin and mounted 
with Entellan (Merck KGaA, Darmstadt, Hessen, 
Germany). Sections of amygdala and of oral 
squamous cell carcinoma were used as positive 
controls for p21WAF1 and p53, respectively. Negative 
controls were provided by omission of the primary 
antibody in sections of the same lesions used as 
positive controls.
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Images of five selected fields indicative of the 
epithelial disorder under investigation were captured 
at 200x magnification using the Qcapture software 
version 2.81 (Quantitative Imaging Corporation, 
Inc.; Surrey, BC, Canada) in addition to a binocular 
microscope CX41RF model (Olympus Latin America 
Inc., Miami, FL, USA) coupled to a camera Qcolor 
5, Coolet, RTV (Olympus Latin America Inc.) and 
Case HD Age Gender Location p21WAF1 p53
BL
(+ cells %)
PL
(+ cells %)
IL SL BL
(+ cells %)
PL
(+ cells %)
IL SL
1 ED 65 M Lower lip 4.4 4.4 + - 38.4 38.8 +
2 ED 41 M Tongue 13.4 35.8 + - 44.2 71 + -
3 ED 29 F Tongue 2.8 25.6 + - 82.6 80.4 + +
4 ED 57 F Tongue 5.4 38 + - 54.2 69.2 + -
5 ED 59 F Gingiva 3.8 34.8 + - 13 36.6 + -
6 ED 75 F Tongue 1.8 24.6 + - 66.2 85.2 + -
7 ED 46 F Gingiva 1 27.2 + - 51.4 37 + -
8 ED 77 M Tongue 2 19.8 + - 36.6 32.2 + -
9 ED 44 M Buccal 
mucosa
2.8 17 + - 15.2 26 + -
10 ED 47 M Tongue 13.2 51.6 + - 41.4 42.2 + +
11 ED 55 M Tongue 3.6 26.6 + - 50.4 61.4 + -
12 A 29 M Tongue 0 7.6 - - 42 42.4 + -
13 A 31 F Buccal 
mucosa
3.6 28.2 + - 68.2 68.8 + +
14 A 53 M Lower lip 11.8 39.8 + - 81.8 84.8 + +
15 A 42 F Gingiva 0.6 29 + - 6.6 4.8 + +
16 A 72 M Buccal 
mucosa
5 18.2 + - 42.6 51.6 + -
17 A 47 F Lower lip 5.8 36.4 + - 16.6 31.6 + +
18 H 67 F Gingiva 4.4 17 + + 55 76.4 + +
19 H 71 F Gingiva 0 1.6 + + 51.6 55.4 + +
20 H 28 M Tongue 15.2 36.2 - - 79.4 87.4 + +
21 H 46 F Gingiva 0.6 14.6 + - 12.4 27.2 + +
22 H 65 M Gingiva 2.4 25 + - 28 39.2 + -
23 H 71 M Gingiva 0 0.4 + - 44.4 40.8 + -
24 H 43 M Tongue 13 15.4 + + 71.6 68.6 + -
25 H 41 M Lower lip 2.4 24.8 + - 74.4 75.4 + +
26 H 44 F Gingiva 0 12.6 - - 12 11.6 + -
27 AH 42 M Buccal 
mucosa
2.8 30.2 + - 36.6 36.8 + -
28 AH 37 M Palate 2 3.6 - - 41.6 51.2 + +
29 AH 62 F Gingiva 5.4 4.8 + - 34.2 22.6 + +
30 AH 34 F Buccal 
mucosa
4.2 38.2 + + 78.6 68.6 + +
31 AH 66 M Gingiva 3.2 13.6 + - 62.2 72.2 + -
32 AH 50 M Lower lip 4.2 22.6 + - 89.6 89.4 + +
33 AH 24 F Buccal 
mucosa
3 16 + - 61.4 57.4 + +
34 AH 47 F Lower lip 1.2 21.2 + - 46.6 55.2 + +
35 AH 44 M Buccal 
mucosa
2.8 33 + - 26.6 27 + -
36 AH 54 F Buccal 
mucosa
10.4 26 + - 57.6 58 + +
Table 1- Clinicopathological characteristics of leukoplakias and patterns of p53 and p21WAF1 immunostaining
HD=Histopathological diagnosis; ED=Epithelial dysplasia; A=Acanthosis; H=Hyperkeratosis; AH=Acanthosis and 
Hyperkeratosis; M=Male; F=Female; BL=Basal Layer; PL=Parabasal Layer; IL=Intermediate Layer; SL=Superficial Layer
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connected to a computer (Dimension 5150, Dell, 
Eldorado do Sul, RS, Brazil). Microscopic fields with 
subepithelial inflammatory infiltrate, overlapping 
cells, and artifact areas were excluded.
ImageTool for Windows version 3.0 (Health 
Science Center, University of Texas, San Antonio, 
TX, USA) was used to count 500 cells from the 
basal layer and 500 from the parabasal layer, thus 
determining the percentage of cells marked as 
positive. Cells were classified as positive when their 
nuclei were brown-stained. A qualitative analysis 
was also carried out to determine the presence or 
absence of immunohistochemical staining in the 
intermediate and superficial layers. Layers were 
defined as follows: the basal layer was defined as 
containing cells with at least one point of contact 
with the basement membrane; the parabasal layer 
was composed of cell layers immediately above the 
basal layer, the shape of the cells was not flattened; 
the superficial layer was characterized by the most 
superficial cells, presenting a typical flattened 
shape; and the intermediate layer was defined as 
containing epithelial cells between the parabasal 
layer and the superficial layer11. Analysis and 
quantification were performed by a single observer 
blinded to the group to which the lesions belonged 
(the fields had been coded).
Intraexaminer calibration was performed by 
means of a second analysis of one in every 10 
fields observed and calculated via the intraclass 
correlation coefficient (ICC=0.996 for the basal 
layer and ICC=0.994 for the parabasal layer). For 
qualitative variables, the Kappa (k=1) test was 
used, showing no statistically significant differences 
between readings. The SPSS software for Windows 
version 11.0 was used to analyze the results. The 
statistical analyses met assumptions of normality 
and homogeneity of variance. Therefore, groups 
were compared with ANOVA considering a 5% 
significance level (p<0.05). Pearson’s correlation 
coefficient was used to test for associations 
between the two markers, p53 and p21WAF1. The 
study was independently reviewed and approved 
by the Research ethics Committee at the School of 
Dentistry, Universidade Federal do Rio Grande do 
Sul (protocol no. 01/07).
RESULTS
The sample was comprised of 6 specimens of 
acanthosis, 9 of hyperkeratosis, 10 of acanthosis 
combined with hyperkeratosis and 11 of epithelial 
dysplasia. The mean age of patients was 50.13 
(±14.51) years old, 19 were male and 17 female. 
The most common anatomic site of the leukoplakias 
was gingiva (n=11) followed by tongue (n=10), 
buccal mucosa (n=8), lip (=6) and palate (n=1). 
All clinicopathological characteristics of the sample 
are specified on Table 1. The patient’s follow-up 
ranged from 3 to 6 years, and no recurrence, new 
leukoplakia lesion or progression to oral squamous 
cell carcinoma was observed. 
All leukoplakia samples showed positive 
immunohistochemical staining results for the proteins 
p53 and p21WAF1 (Figure 1). The mean percentage of 
p53 staining in the basal and parabasal layers was 
similar, ranging from 42 to 53% in all four groups. 
On the other hand, p21WAF1 staining differed between 
layers: in the basal layer, only 3 to 4% of cells were 
stained, while in the parabasal layer, between 16 and 
27% of the epithelial cells were stained in the four 
Figure 1- p53 and p21WAF1 expression in oral leukoplakias. 
Leukoplakias with: epithelial dysplasia (DE); acanthosis 
(A); acanthosis in combination with hyperkeratosis (AH); 
hyperkeratosis (H). p53 and p21WAF1 immunohistochemical 
expressions are shown in the left and right columns, 
respectively
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different studied groups. No statistically significant 
differences (p>0.05) were observed between the 
groups for immunohistochemical staining for p53 
and p21WAF1 (Tables 2 and 3).
Table 4 lists the number of specimens with positive 
staining results in the intermediate and superficial 
layers. Pearson’s correlation coefficient showed a 
weak but significant direct correlation between p53 
and p21WAF1 in basal layer cells (R=0.361), but not 
in the parabasal layer (R=0.250).
DISCUSSION
The results of the present study show that p53 
and p21WAF1 are overexpressed in oral leukoplakias, 
both dysplastic and non-dysplastic ones. One 
important finding is that dysplastic and non-
dysplastic leukoplakias showed similar profiles of 
p53 and p21WAF1 immunostaining. Oral leukoplakia 
has been extensively studied in the literature, 
and most studies have compared dysplastic with 
Table 2- Distribution across groups of mean numbers and mean percentages of p53 positive cells with standard errors 
(±SE) for the basal and parabasal layers
Groups Mean n±SE Mean %±SE p
BASAL LAYER
Epithelial dysplasia 224.36±30.37 44.87±06.07
Acanthosis 214.50±58.91 42.90±11.78
Hyperkeratosis 238.22±42.81 47.64±08.56 0.79
Acanthosis + hyperkeratosis 267.50±31.88 53.50±06.38
PARABASAL LAYER
Epithelial dysplasia 263.64±31.80 52.73±06.36
Acanthosis 236.67±57.47 47.33±11.49
Hyperkeratosis 267.78±42.48 53.56±08.50 0.951
Acanthosis + hyperkeratosis 269.20±32.68 53.84±06.54
Table 3- Distribution across groups of mean numbers and mean percentages of p21WAF1 positive cells with standard errors 
(±SE) for the basal and parabasal layers
Groups Mean n±SE Mean %±SE p
BASAL LAYER
Epithelial dysplasia 24.64±6.51 4.93±1.30
Acanthosis 22.33±8.73 4.47±1.75
Hyperkeratosis 21.11±9.70 4.22±1.94 0.96
Acanthosis + hyperkeratosis 19.60±4.06 3.92±0.81
PARABASAL LAYER
Epithelial dysplasia 138.82±18.64 27.76±3.73
Acanthosis 132.67±24.33 26.53±4.87
Hyperkeratosis 82.00±18.92 16.40±3.78 0.165
Acanthosis + hyperkeratosis 104.60±18.23 20.92±3.65
Groups total (n) p53 p21WAF1
Intermediate + Superficial + Intermediate + Superficial +
Epithelial Dysplasia 11 11 (100%) 3 (27%) 11 (100%) 0 (0%)
Acanthosis 6 6 (100%) 4 (66%) 5 (83%) 0 (0%)
Hyperkeratosis 9 9 (100%) 5 (55%) 7 (77%) 3 (33%)
Acanthosis + 
hyperkeratosis
10 10 (100%) 7 (70%) 9 (90%) 1 (10%)
Table 4- Distribution of samples exhibiting positive p53 and p21WAF1 staining in the intermediate and superficial layers
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the non-dysplastic leukoplakias classified into a 
single group. This study assessed p53 and p21WAF1 
immunolabeling of the three most common non-
dysplastic leukoplakias.
A significant number of leukoplakias in which 
epithelial dysplasia is not detected on biopsy may 
undergo malignant transformation7,8,20. Therefore, 
it is lacking in the literature information about 
differences in behavior profiles among the different 
histologic subtypes of non-dysplastic leukoplakias. 
Although no differences were observed in the 
present study, Hildebrand, et al.6 (2010), analyzing 
cell proliferation rate through AgNOR staining, 
verified that between different subtypes of non-
dysplastic leukoplakias only the acanthosis group 
showed a proliferative behavior similar to that found 
in epithelial dysplasia.
In all epithelial disorders assessed here, the 
immunohistochemical labeling of p53 was altered. 
Under physiological conditions, p53 expression 
should be restricted to a few cells in the epithelial 
basal layer21. However, a larger number of 
immunohistochemically stained cells was found 
in all layers of the samples without differences 
between the groups. In the present study, we did 
not grade dysplasia samples due to the difficulties 
involved in reaching a diagnostic consensus and 
to the subjectivity involved in grading epithelial 
dysplasia17,29. Additionally, epithelial dysplasia were 
classified as absent or present, mainly because our 
focus was to analyze the non-dysplastic leukoplakias 
and use dysplasia just as a comparison group.
Despite the large number of studies about 
p53 immunohistochemical labeling, a closer 
comparison with previous works is difficult. 
There is no standardization of staining methods, 
antibody clones, sensitivity of the detection system 
or quantification and interpretation of results4. 
Several studies have shown a correlation between 
immunohistochemical p53 labeling and mutation of 
the TP53 gene. However, under certain conditions, 
the wild type protein may be accumulated in cells 
as a response of different types of cellular stress, 
as result of the association between the wild type 
p53 and other proteins, or of the disruption of 
its degradation pathway, making it more easily 
detectable15. The clone DO-7 monoclonal antibody 
used in this study recognizes both proteins16.
A possible explanation for the increased 
expression of p53 in this sample could be the 
presence of genetic damage, which may lead to 
oral cancer if progressively accumulated. Studies 
have shown that genetic alterations can occur in 
early stages of oral carcinogenesis, particularly 
at chromosome 3, in keratotic and non-dysplastic 
lesions23. However, we observed a positive correlation 
between p53 and p21WAF1 expression; usually, a 
p53-independent induction of p21WAF1 takes place in 
response to cell differentiation signals, while p53-
dependent induction occurs in response to cellular 
stress27. The observed correlation contradicts other 
studies that did not detect such association and 
which have suggested that mechanisms independent 
of the action of p53 are involved in inducing p21WAF1 
expression in potentially malignant lesions and oral 
cancer14,26.
p21WAF1 staining was observed mainly in the 
parabasal layer of the epithelium, with isolated 
positive cells in the basal layer, which is in 
agreement with the results of other studies3,22, and 
the rate of positive cells was also similar between 
the groups. There is evidence that as the epithelial 
abnormalities progress from dysplasia to squamous 
cell carcinoma, p21WAF1 labeling increases in number 
of positive cells, and from being restricted to the 
parabasal layer it extends to all epithelial layers3,22. 
While in normal epithelium p53 and p21WAF1 are 
detectable only in basal layer or in few isolated 
cells, in the parabasal layer it is observed that as 
the severity of the epithelial alteration increases 
the expression of these proteins seems to up rise 
through the epithelium. Most studies on p53 and 
p21WAF1 labeling discriminate just two layers, the 
basal and all other layers are assessed as a single 
suprabasal layer. In this study, we decided to analyze 
4 different epithelium layers to have a more detailed 
visualization of this phenomenon.
The reason why p21WAF1 expression increases 
in association with oral carcinogenesis has not yet 
been elucidated. This increase could represent 
an attempt to control cell proliferation, which is 
possibly overcome by other factors which stimulate 
carcinogenesis and overload the inhibitory function 
of p21WAF1. Alternatively, the action held by p21WAF1 
could be favoring cell proliferation5,30, since the 
inhibitory function of p21WAF1 is stechiometrically 
regulated: many molecules of p21WAF1 are needed 
to inhibit a cyclin-CDK complex, whereas a single 
molecule may favor active cyclin-CDK complex 
binding31.
Although surgical removal still seems to be 
the predominant method of treatment of oral 
leukoplakias, there remains little evidence that 
there is a reliable and safe method to prevent the 
recurrence of leukoplakias, and the potential for oral 
squamous cell carcinoma development12, since no 
randomized controlled trials have been undertaken 
to test this hypothesis. We have opted for including 
only lesions smaller than 2 cm so that excisional 
biopsy could be performed because, even though 
there is no evidence of its efficacy, it allows us 
identifying the true nature of leukoplakia, as many 
studies have shown that incisional biopsies are not 
representative of the whole lesion8.
In the present study, the inclusion criteria were 
established to standardize some aspects of the 
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sample, such as clinical aspect and lesion size, so 
we could focus on the histopathological finding and 
its significance for the leukoplakia behavior. So far 
no recurrence or transformation was observed.
CONCLUSION
The different types of non-dysplastic lesions 
showed similar profiles of p53 and p21WAF1 staining. 
The lack of significant differences between non-
dysplastic leukoplakias and dysplastic leukoplakias 
is in agreement with recent data presented in 
the literature. There is no consensus on the most 
appropriate management for non-dysplastic 
leukoplakias. While this question is not answered, our 
findings suggest that all leucoplakias, independent 
of their histopathological diagnosis, must be 
considered as potentially malignant disorders and 
the patients should be kept under regular long-term 
clinical follow-up with a specialist.
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